A cumulative dose safety and tolerability crossover study of arformoterol tartrate inhalation solution and levalbuterol hydrochloride [levosalbutamol] inhalation solution in pediatric subjects (aged 2 to 11 years of age) with asthma.

Trial Profile

A cumulative dose safety and tolerability crossover study of arformoterol tartrate inhalation solution and levalbuterol hydrochloride [levosalbutamol] inhalation solution in pediatric subjects (aged 2 to 11 years of age) with asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2012

At a glance

  • Drugs Arformoterol; Levosalbutamol
  • Indications Asthma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2011 Results published in Pediatric Pulmonology.
    • 12 Feb 2010 Actual patient number (53) added as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top